Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of migraine or chronic migraine.
History of migraine headaches at least 1 year prior to screening, with onset prior to age 50.
History of at least 4 migraine headache days and at, with at least 1 headache-free day per month on average within the past 3 months.
Have documentation of 2 to 4 migraine preventive medication category failures due to inadequate efficacy or tolerability, in the past 10 years.
You may not be if
Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.
Current use or prior exposure to galcanezumab or another calcitonin gene-related peptide (CGRP) antibody.
History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine).
Pregnant or nursing.
Clareo Health | A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
